{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.6","upperLimit":"41.1","value":"22.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"DCR defined as the percentage of patients with confirmed CR, PR, or stable disease (SD) for ≥ 16 weeks","dispersionType":"95% Confidence Interval","groups":[{"description":"260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle","id":"OG000","title":"Milademetan (RAIN-32)"}],"paramType":"NUMBER","populationDescription":"The efficacy analysis is conducted in all participants within the Centrally confirmed population (CCP).","reportingStatus":"POSTED","timeFrame":"From first dose date to first CR, PR, or stable disease (SD) >= 16 weeks, or study completion date; up to 23.5 months","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}